[{"orgOrder":0,"company":"Vaxxas","sponsor":"Bill & Melinda Gates Foundation ","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Measles vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxas","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Vaxxas \/ Bill & Melinda Gates Foundation ","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxas \/ Bill & Melinda Gates Foundation "},{"orgOrder":0,"company":"Vaxxas","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Vaxxas","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Vaxxas \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Vaxxas \/ Merck"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"HD-MAP","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxas \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"Recombinant SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxas \/ The University of Texas","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ The University of Texas"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"HexaPro","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"OneVentures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"HexaPro","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ OneVentures","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ OneVentures"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Inactivated Seasonal Influenza Vaccine Quadrivalent","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"HexaPro","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Wellcome","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Typhoid Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Wellcome","highestDevelopmentStatusID":"5","companyTruncated":"Vaxxas \/ Wellcome"},{"orgOrder":0,"company":"Vaxxas","sponsor":"SK Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Typhoid Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ SK bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxas \/ SK bioscience"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"H7N9-targeted Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaxxas \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vaxxas \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"RSV Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaxxas \/ Vaxxas","highestDevelopmentStatusID":"14","companyTruncated":"Vaxxas \/ Vaxxas"}]

Find Clinical Drug Pipeline Developments & Deals by Vaxxas

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : NIH has granted the company a license to a next-generation vaccine antigen (DS2), designed for use in prophylactic vaccines against Respiratory Syncytial Virus (RSV).

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : RSV Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : National Institutes of Health

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Vaxxas’ high-density microarray patch (HD-MAP) technology uses an array of microprojections to deliver the vaccine, against pre-pandemic avian influenza strain H7N9, to the skin.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 11, 2024

                          Lead Product(s) : H7N9-targeted Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Under the collaboration, SK bioscience will supply the antigen utilized by its typhoid conjugate vaccine, SKYTyhpoid to develop a novel vaccine-delivery device combination product using Vaxxas’ high-density microarray patch (HD-MAP) platform technology...

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 24, 2023

                          Lead Product(s) : Typhoid Conjugate Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : SK Bioscience

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The funding will support the IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine delivered by Vaxxas’ proprietary high-density microarray patch platform technology.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 23, 2023

                          Lead Product(s) : Typhoid Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Wellcome

                          Deal Size : $3.6 million

                          Deal Type : Funding

                          blank

                          05

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : HexaPro, a second-generation version of the spike protein used in all major U.S. approved COVID-19 vaccines, which was modified to be more stable and immunogenic than its predecessor, giving potential coverage of all known SARS-CoV-2 variants.

                          Brand Name : HexaPro

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          June 05, 2023

                          Lead Product(s) : HexaPro

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The vaccine being delivered by the Vaxxas HD-MAP in this Phase I clinical trial is a commercially available seasonal flu vaccine (IIV4) targeting four significant strains of the influenza virus.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          February 09, 2023

                          Lead Product(s) : Inactivated Seasonal Influenza Vaccine Quadrivalent

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The financing will accelerate the clinical program for Vaxxas’ COVID-19 vaccine patch candidate which is based upon the company’s proprietary HD-MAP delivery of HexaPro, a second-generation version of the spike protein used in all major US-approved C...

                          Brand Name : HexaPro

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 05, 2022

                          Lead Product(s) : HexaPro

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : OneVentures

                          Deal Size : $23.0 million

                          Deal Type : Financing

                          blank

                          08

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : HexaPro, a highly stabilized protein that is designed to mimic the structure of the spike protein on the surface of the coronavirus to train the human immune system to recognize and fight SARS-CoV-2 infection.

                          Brand Name : HexaPro

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          November 08, 2022

                          Lead Product(s) : HexaPro

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The license obtained by Vaxxas from the United States’ National Institutes of Health, enables Vaxxas to create the first needle-free, room-temperature stable, SARS-CoV-2 spike subunit vaccine (HexaPro) patch to enter clinical studies.

                          Brand Name : HexaPro

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 23, 2022

                          Lead Product(s) : Recombinant SARS-CoV-2 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : The University of Texas MD Anderson Cancer Center

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          10

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Vaccination via HD-MAP induced enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery of the same vaccine in an animal model.

                          Brand Name : HD-MAP

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          June 02, 2021

                          Lead Product(s) : HD-MAP

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank